{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:05:35Z","timestamp":1791162335275,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T00:00:00Z","timestamp":1164844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T00:00:00Z","timestamp":1164844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,2,1]]},"DOI":"10.1038\/sj.leu.2404471","type":"journal-article","created":{"date-parts":[[2006,11,30]],"date-time":"2006-11-30T09:53:54Z","timestamp":1164880434000},"page":"333-339","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma"],"prefix":"10.1038","volume":"21","author":[{"given":"T","family":"Haritunians","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"O'Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q T","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F J","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H P","family":"Koeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,30]]},"reference":[{"key":"BF2404471_CR1","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","volume":"87","author":"DD Weisenburger","year":"1996","unstructured":"Weisenburger DD, Armitage JO . Mantle cell lymphoma \u2013 an entity comes of age. Blood 1996; 87: 4483\u20134494.","journal-title":"Blood"},{"key":"BF2404471_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/315340a0","volume":"315","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM . Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 1985; 315: 340\u2013343.","journal-title":"Nature"},{"key":"BF2404471_CR3","first-page":"2159","volume":"9","author":"J Lukas","year":"1994","unstructured":"Lukas J, Jadayel D, Bartkova J, Nacheva E, Dyer MJ, Strauss M et al. BCL-1\/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation. Oncogene 1994; 9: 2159\u20132167.","journal-title":"Oncogene"},{"key":"BF2404471_CR4","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1182\/blood.V84.8.2726.2726","volume":"84","author":"F Bosch","year":"1994","unstructured":"Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N et al. PRAD-1\/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84: 2726\u20132732.","journal-title":"Blood"},{"key":"BF2404471_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1101\/gad.7.3.331","volume":"7","author":"J Kato","year":"1993","unstructured":"Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ . Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331\u2013342.","journal-title":"Genes Dev"},{"key":"BF2404471_CR6","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","volume":"79","author":"CJ Sherr","year":"1994","unstructured":"Sherr CJ . G1 phase progression: cycling on cue. Cell 1994; 79: 551\u2013555.","journal-title":"Cell"},{"key":"BF2404471_CR7","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/sj.leu.2403968","volume":"19","author":"RH Xu","year":"2005","unstructured":"Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P . Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005; 19: 2153\u20132158.","journal-title":"Leukemia"},{"key":"BF2404471_CR8","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1101\/gad.887201","volume":"15","author":"AC Gingras","year":"2001","unstructured":"Gingras AC, Raught B, Sonenberg N . Regulation of translation initiation by FRAP\/mTOR. Genes Dev 2001; 15: 807\u2013826.","journal-title":"Genes Dev"},{"key":"BF2404471_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ccr.2005.08.008","volume":"8","author":"N Hay","year":"2005","unstructured":"Hay N . The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8: 179\u2013183.","journal-title":"Cancer Cell"},{"key":"BF2404471_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nrm1018","volume":"4","author":"E Jacinto","year":"2003","unstructured":"Jacinto E, Hall MN . Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003; 4: 117\u2013126.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BF2404471_CR11","first-page":"1527","volume":"61","author":"B Geoerger","year":"2001","unstructured":"Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor\/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527\u20131532.","journal-title":"Cancer Res"},{"key":"BF2404471_CR12","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","volume":"65","author":"L Wu","year":"2005","unstructured":"Wu L, Birle DC, Tannock IF . Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65: 2825\u20132831.","journal-title":"Cancer Res"},{"key":"BF2404471_CR13","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C Recher","year":"2005","unstructured":"Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527\u20132534.","journal-title":"Blood"},{"key":"BF2404471_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252\u2013261.","journal-title":"Cancer Res"},{"key":"BF2404471_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ygyno.2005.12.019","volume":"102","author":"O Treeck","year":"2006","unstructured":"Treeck O, Wackwitz B, Haus U, Ortmann O . Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 2006; 102: 292\u2013299.","journal-title":"Gynecol Oncol"},{"key":"BF2404471_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/jnci\/95.12.896","volume":"95","author":"T Kumagai","year":"2003","unstructured":"Kumagai T, O'Kelly J, Said JW, Koeffler HP . Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma and colon cancer cells. J Natl Cancer Inst 2003; 95: 896\u2013905.","journal-title":"J Natl Cancer Inst"},{"key":"BF2404471_CR17","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A et al. Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12: 5165\u20135173.","journal-title":"Clin Cancer Res"},{"key":"BF2404471_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","volume":"66","author":"H Yan","year":"2006","unstructured":"Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M et al. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis. Cancer Res 2006; 66: 2305\u20132313.","journal-title":"Cancer Res"},{"key":"BF2404471_CR19","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/sj.leu.2403848","volume":"19","author":"J Dengler","year":"2005","unstructured":"Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J . Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 2005; 19: 1835\u20131838.","journal-title":"Leukemia"},{"key":"BF2404471_CR20","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE . Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409\u20136414.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/cncr.21313","volume":"104","author":"C Thieblemont","year":"2005","unstructured":"Thieblemont C, Antal D, Lacotte-Thierry L, Delwail V, Espinouse D, Michallet AS et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104: 1434\u20131441.","journal-title":"Cancer"},{"key":"BF2404471_CR22","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/sj.leu.2401121","volume":"12","author":"H Samaha","year":"1998","unstructured":"Samaha H, Dumontet C, Ketterer N, Moullet I, Thieblemont C, Bouafia F et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12: 1281\u20131287.","journal-title":"Leukemia"},{"key":"BF2404471_CR24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/00001622-200109000-00005","volume":"13","author":"JP Leonard","year":"2001","unstructured":"Leonard JP, Schattner EJ, Coleman M . Biology and management of mantle cell lymphoma. Curr Opin Oncol 2001; 13: 342\u2013347.","journal-title":"Curr Opin Oncol"},{"key":"BF2404471_CR25","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489\u2013501.","journal-title":"Nat Rev Cancer"},{"key":"BF2404471_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E . mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525\u2013537.","journal-title":"Ann Oncol"},{"key":"BF2404471_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","volume":"83","author":"G Lenz","year":"2004","unstructured":"Lenz G, Dreyling M, Hiddemann W . Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83: 71\u201377.","journal-title":"Ann Hematol"},{"key":"BF2404471_CR28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/sj.leu.2402302","volume":"15","author":"M Ladetto","year":"2001","unstructured":"Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo\/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941\u20131949.","journal-title":"Leukemia"},{"key":"BF2404471_CR29","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587\u2013593.","journal-title":"Leukemia"},{"key":"BF2404471_CR31","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1074\/jbc.M309999200","volume":"279","author":"JF Gera","year":"2004","unstructured":"Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004; 279: 2737\u20132746.","journal-title":"J Biol Chem"},{"key":"BF2404471_CR32","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","volume":"106","author":"R Avellino","year":"2005","unstructured":"Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, Poggi V et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400\u20131406.","journal-title":"Blood"},{"key":"BF2404471_CR33","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347\u20135356.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR34","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2004-11-4513","volume":"106","author":"F Jundt","year":"2005","unstructured":"Jundt F, Raetzel N, Muller C, Calkhoven CF, Kley K, Mathas S et al. A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005; 106: 1801\u20131807.","journal-title":"Blood"},{"key":"BF2404471_CR35","first-page":"1433","volume":"90","author":"S Hipp","year":"2005","unstructured":"Hipp S, Ringshausen I, Oelsner M, Bogner C, Peschel C, Decker T . Inhibition of the mammalian target of rapamycin and the induction of cell-cycle arrest in mantle cell lymphoma cells. Haematologica 2005; 90: 1433\u20131434.","journal-title":"Haematologica"},{"key":"BF2404471_CR36","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","volume":"65","author":"SY Sun","year":"2005","unstructured":"Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052\u20137058.","journal-title":"Cancer Res"},{"key":"BF2404471_CR37","first-page":"1758","volume":"7","author":"L Dudkin","year":"2001","unstructured":"Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7: 1758\u20131764.","journal-title":"Clin Cancer Res"},{"key":"BF2404471_CR38","doi-asserted-by":"publisher","first-page":"13907","DOI":"10.1074\/jbc.M110782200","volume":"277","author":"MB Dilling","year":"2002","unstructured":"Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907\u201313917.","journal-title":"J Biol Chem"},{"key":"BF2404471_CR39","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/cncr.20245","volume":"100","author":"DA Rizzieri","year":"2004","unstructured":"Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ et al. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. Cancer 2004; 100: 2408\u20132414.","journal-title":"Cancer"},{"key":"BF2404471_CR40","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/sj.leu.2402639","volume":"16","author":"C Kosmas","year":"2002","unstructured":"Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T . Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002; 16: 2004\u20132015.","journal-title":"Leukemia"},{"key":"BF2404471_CR41","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705\u2013711.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","volume":"33","author":"S Sakajiri","year":"2005","unstructured":"Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP . Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 2005; 33: 53\u201361.","journal-title":"Exp Hematol"},{"key":"BF2404471_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ . Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell-cycle arrest and apoptosis. J Immunol 2003; 171: 88\u201395.","journal-title":"J Immunol"},{"key":"BF2404471_CR44","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00428-005-1264-9","volume":"446","author":"X Dolcet","year":"2005","unstructured":"Dolcet X, Llobet D, Pallares J, Matias-Guiu X . NF-\u03baB in development and progression of human cancer. Virchows Arch 2005; 446: 475\u2013482.","journal-title":"Virchows Arch"},{"key":"BF2404471_CR45","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676\u2013684.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR46","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667\u2013675.","journal-title":"J Clin Oncol"},{"key":"BF2404471_CR47","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420\u20134427.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404471","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404471.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:45:01Z","timestamp":1648781101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,30]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2,1]]}},"alternative-id":["BF2404471"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404471","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,30]]},"assertion":[{"value":"14 March 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}